GEXVal Invited to Speak at Certainty Japan 2026

GEXVal Inc.
June 18, 2026

GEXVal Head of R&D CMC Selected as Invited Speaker at Certainty Japan 2026

GEXVal Inc. (President & CEO: Juran Kato, PhD; Fujisawa, Kanagawa, Japan; hereinafter “GEXVal”) is pleased to announce that Dr. Toshitake Kobayashi, Head of R&D CMC, has been invited to speak at Certainty Japan 2026, hosted by Certara, Inc.

[Event Overview]
"Certainty Japan" is an annual conference hosted by Certara, Inc., bringing together leading experts in clinical pharmacology and biosimulation. The event serves as a premier forum for discussing the practical application of modeling and simulation technologies — including Model-Informed Drug Development (MIDD) — as well as the latest regulatory developments, while also providing valuable networking opportunities for researchers and professionals across the pharmaceutical industry.
This year's program has been expanded to include two dedicated afternoon tracks alongside the morning plenary sessions: "Modeling & Simulation Updates and Case Studies" and "AI-Enabled Discovery & Candidate Assessment."
Dr. Toshitake Kobayashi will deliver a guest lecture featured across both tracks, covering GEXVal's AI-assisted drug discovery approach for patients with rare diseases and other underserved medical conditions, and sharing insights from early-stage clinical development via Australia.

**Presentation Details**

[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.

For further information:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com